Status:

COMPLETED

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Lead Sponsor:

Cooperative International Neuromuscular Research Group

Conditions:

Muscular Dystrophy, Duchenne

Eligibility:

MALE

7+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to see if male children with Duchenne muscular dystrophy (DMD) have changes in strength when given the drug Pentoxifylline as a rescue treatment. A total of 64 subjects ar...

Detailed Description

DMD is the most common and devastating type of muscular dystrophy (incidence 1 in 3500 live born males worldwide). DMD is characterized by a complete loss of dystrophin, leading to progressive muscle ...

Eligibility Criteria

Inclusion

  • Male
  • Age 7 years to 100 years
  • Ability to ambulate for 10 meters. Assistive devices are allowed.
  • Diagnosis of DMD confirmed by at least one the following:
  • On stable dose of prednisone, prednisolone or deflazacort for at least 12 months prior to screening.
  • Participants who are on stable dose of any combination of the following compounds (creatine, glutamine, coenzyme Q10, vitamin E, C or D, JUVEN, arginine, calcium) must have taken these medications for at least 2 months prior to screening. Subjects are not required to take these medications to participate in the study.
  • All other herbs, supplements or green tea (other than those noted above) have been discontinued 3 months prior to screening.
  • Ability to provide reproducible QMT bicep score with no more than 15% variation between scores during screening.
  • Normal blood clotting ability evidenced by a platelet function assessment (PFA).

Exclusion

  • Currently enrolled in another treatment clinical trial.
  • History of significant concomitant illness or significant impairment of renal or hepatic function.
  • History of impairment of blood clotting ability (as evidenced by increased PT/PTT or PFA over the upper limit of normal (ULN)).
  • Recent cerebral or retinal hemorrhage.
  • History of bleeding diathesis or gastric ulcer.

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2008

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT00243789

Start Date

September 1 2005

End Date

January 1 2008

Last Update

October 27 2011

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

2

Mayo Clinic

Rochester, Minnesota, United States, 55905

3

Washington University, St. Louis

St Louis, Missouri, United States, 63110

4

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy | DecenTrialz